January 27, 2022
Cravath partner John D. Buretta authored a chapter on cooperating with U.S. authorities during a government investigation in Global Investigations Review’s sixth edition of “The Practitioner’s Guide to Global Investigations,” which published in January 2022.
The chapter, entitled “Co‑operating with the Authorities: U.S. Perspective,” was featured in “Volume I: Global Investigations in the United Kingdom and the United States” and co‑authored by Cravath practice attorney Megan Y. Lew. It analyzes how U.S. government authorities define cooperation, the risks and benefits of cooperation and unique challenges presented in multi‑agency and cross‑border investigations.
Deals & Cases
August 24, 2021
On August 24, 2021, Exyte Group (“Exyte”) and Wynnchurch Capital announced that they had reached an agreement for an all-share acquisition of Critical Process Systems Group, a group of manufacturing and design companies, by Exyte, a global leader in the design, engineering, and delivery of high-tech facilities. Cravath is representing Exyte in connection with the transaction.
Deals & Cases
August 17, 2021
On July 19, 2021, the U.S. Court of Appeals for the Second Circuit affirmed the district court’s dismissal of a second consolidated amended class action complaint alleging a violation of Section 1 of the Sherman Act as to Cravath client Nomura International plc and several other defendants.
Deals & Cases
July 30, 2021
On July 28, 2021, Swvl Inc. (“Swvl”), a Dubai‑based provider of transformative mass transit and shared mobility solutions, and Queen’s Gambit Growth Capital, the first special purpose acquisition company entirely led by women, announced that they have entered into a definitive agreement for a business combination that would result in Swvl becoming a publicly listed company. Upon completion of the proposed transaction, the combined public company will be named Swvl Holdings Corp and is expected to be the first $1 billion plus “unicorn” from the Middle East to list on NASDAQ, under the ticker symbol “SWVL”. Cravath is representing Swvl in connection with the transaction.
Deals & Cases
April 12, 2021
On April 11, 2021, DiaSorin S.p.A. (“DiaSorin”), a leading global diagnostics company, announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex”), a leader in multiplexing technology, for a price of $37.00 per share in an all‑cash transaction corresponding to an enterprise value of approximately $1.8 billion. Cravath is representing DiaSorin in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.